Partillion Bioscience

Executive Summary

Partillion Bioscience has developed Nanovials, a novel platform enabling high-throughput functional single-cell analysis without requiring new capital equipment. By encapsulating individual cells in nanoliter-sized hydrogel particles, the technology captures secreted molecules in situ, facilitating applications in cell therapy development, antibody discovery, and secretome research. This approach addresses a critical bottleneck in the biopharma pipeline by providing direct functional readouts at single-cell resolution, which traditional genomic methods cannot offer. The platform's compatibility with existing lab infrastructure (standard flow cytometers and plate readers) lowers adoption barriers and positions it as a versatile tool for both academic and industrial users. Partillion is headquartered in Los Angeles and operates at the intersection of diagnostics and microbiome research. While still in its early commercial phase, the company's technology has garnered attention for its potential to accelerate therapeutic development and enable new insights into cell function. With a strong intellectual property position and a growing list of early adopters, Partillion is poised for growth as the demand for functional single-cell analysis increases. The management team's background in microfluidics and cell biology further strengthens its execution capability. The company is actively seeking strategic partnerships and commercial deployments to scale its impact.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of Nanovial products (e.g., kits for antibody discovery)65% success
• H1 2027Strategic partnership with a major pharma or CRO for cell therapy development50% success
• Q2 2027Series A financing led by life sciences VCs60% success